These findings are consistent with two other separate studies that showed D+Q was effective in lowering the expression of p16 and SA‐β‐gal in patients with diabetic kidney disease and idiopathic pulmonary disease during a phase I clinical trial (Hickson et al., 2019; Justice et al., 2019). The gene discussed is CDKN2A; the disease is diabetic kidney disease.